Dr. Tarantolo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8303 Dodge St
Suite 250
Omaha, NE 68114Phone+1 402-354-8124Fax+1 402-354-5872
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 1988 - 1991
Jersey Shore University Medical CenterResidency, Internal Medicine, 1985 - 1988
St. George's University School of MedicineClass of 1985
Certifications & Licensure
NE State Medical License 1992 - 2026
NJ State Medical License 1986 - 1993- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Most Compassionate Doctor American Registry
Clinical Trials
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
- A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 162 citationsPembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo
The Lancet. Haematology. 2019-09-01 - 173 citationsPembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18 - 29 citationsC‐erb‐B2 (HER2/neu) expression in synovial sarcoma of the head and neckRandall J. Olsen, William M. Lydiatt, Scott A. Koepsell, Daniel D. Lydiatt, Sonny L. Johansson
Head & Neck. 2005-10-01
Press Mentions
Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021- Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021
Finding Inner Peace Through Inner BeautyMay 21st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
